Healthcare
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company's post-marketing study "ChoICE," (the "ChoICE Study"), for ProSense® in the treatment of low-risk breast cancer following U.S Food and Dr
About this update from Icecure Medical Ltd.
Company signed agreement with the West Cancer Center & Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer CAESAREA, Israel, July 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company's post-marketing study "ChoICE," (the "ChoICE Study"), for ProSense® in the treatment of low-risk breast cancer following U.S Food and Drug Administration ("FDA") marketing authorization in October 2025. The ChoICE Study will enroll up to 400 patients across 30 U.S. sites, gathering real-world data to support further clinical adoption and broader access for eligible patients. "We are pleased to welcome West Cancer Center & Research Institute to the ChoICE Study," said Eyal Shamir, Chief Executive Officer of IceCure Medical. "We believe each new site adds important momentum as we work with leading clinical teams across the U.S. to expand real-world experience with ProSense® and support broader access to minimally invasive cryoablation for eligible breast cancer patients." The ChoICE Study builds on the Company's clinical efforts in breast cancer cryoablation, demonstrating its ongoing commitment to advancing evidence-based care for leading cancer diagnosis in women globally. The site will be led by Dr. Richard Gilmore, MD, MBA, DipABLM, a breast surgical oncologist at the Margaret West Comprehensive Breast Center, part of West Cancer Center & Research Institute. About the ChoICE Study The ChoICE Study will evaluate ProSense® cryoablation with endocrine therapy for low-risk, early-stage breast cancer in patients aged 70 years and above. ProSense® is cleared by the U.S. Food and Drug Administration ("FDA") for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery. The ChoICE Study aims to generate additional real-world data regarding the use of ProSense® in this indication. Unde...
View stock analysis, news, and events for Icecure Medical Ltd.